FierceBiotech 16 mars 2026 Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years
FierceBiotech 13 mars 2026 Sana sees 14-month insulin production for transplanted islet therapy in single Type 1 diabetes patient
FierceBiotech 13 mars 2026 China approves first brain-computer interface implant for paralyzed patients, as sector heats up
FierceBiotech 13 mars 2026 Stop Asking for an AI strategy: 3 questions clinical leaders should ask instead
FierceBiotech 12 mars 2026 Vistagen lays off 20% of staff to tighten focus on struggling social anxiety candidate
FierceBiotech 12 mars 2026 Pfizer Ignite, designed to accelerate promising biotech therapies, fizzles out
FierceBiotech 12 mars 2026 Fledgling French biotech pens $128M deal for Kezar's preclinical protein degrader program
FierceBiotech 12 mars 2026 Ultragenyx gene therapy hits co-primary endpoint in phase 3 rare disease study, teeing up potential win
FierceBiotech 12 mars 2026 Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom
FierceBiotech 12 mars 2026 Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price